ESTRO 2025 - Abstract Book

S300

Brachytherapy – Head & neck, skin, eye

ESTRO 2025

Conclusion: HyBIRT organ preservation approach showed a better LC (97%), RC (89%) and interestingly DMFS of 85% at 3 & 5 years compared to the historical surgical and definitive radiotherapy series despite 71.4% and 64% of patients in current study having TNM7 T3/T4a and N2 disease (3, 4). Unlike the operative scar recurrence in surgical serie, none of this study patients had skin or dermal lymphatic spread (4). Patients without recurrence at the end of 2-years continue to be disease free at 5-years suggesting cure. Short HDRIBT procedure time, radio-immunomodulation of upfront HDRIBT, IMRT field sterilization and dose escalation are possible postulation for this improved outcome. A multi-centre trial is needed to show the re-producibility of this potentially practice changing clinical outcome in the treatment of OTSCC. References: 1. Appalanaido G, Musa M, Chng E, et al. OC-0631 Upfront HDRIBT followed by IMRT for the Definitive Treatment of Tongue SCC. Radiotherapy and Oncology. 2023;182:S520-S1. 2. Ong KP, Musa MY, Irfan M, Appalanaido GK. Comparing Swallowing Function in OTSCC after HDRIBT followed by IMRT (HyBIRT) with Surgery. Radiotherapy and Oncology. 2024;194:S311-S2. 3. Spiotto MT, Jefferson G, Wenig B et.al. Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg. 2017;143(7):691-9. 4. Shetty KSR, Kurle V, Greeshma et al. Salvage Surgery in Recurrent Oral Sq. Cell Carcinoma. Front Oral Health. 2021;2:815606. Poster Discussion PRO-NOVELTY: Patient-Reported Outcomes in Nose Vestibule Interventional Radiotherapy (Brachytherapy) – An Update Maria Concetta La Milia 1 , Enrico Rosa 2,3 , Bruno Fionda 4 , Elisabetta Sciurti 1 , Antonella Loperfido 5 , Maria Vaccaro 6 , Valentina Lancellotta 4 , Elisa Placidi 2 , Claudio Parrilla 7 , Pierpaolo Dragonetti 4,1 , Mario Rigante 7 , Martina De Angeli 4 , Patrizia Cornacchione 2 , Mariangela Massaccesi 8 , Jacopo Galli 7 , Maria Antonietta Gambacorta 8,1 , Luca Tagliaferri 4,1 , Francesco Bussu 9,10 1 Istituto di Radiologia, Universita` Cattolica del Sacro Cuore, Rome, Italy. 2 UOC Fisica per le Scienze della Vita, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 3 Department of Theoretical and Applied Sciences, eCampus University, Novedrate, Italy. 4 UOC Degenze di Radioterapia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 5 Otolaryngology Unit, San Camillo Forlanini Hospital, Rome, Italy. 6 Medical Physics Unit, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy. 7 U.O.C. Otorinolaringoiatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 8 UOC Servizio di Radioterapia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 9 Otolaryngology Unit, Azienda Ospedaliero Universitaria Sassari, Sassari, Italy. 10 Dipartimento di Medicina, Chirurgia e Farmacia, Universita` di Sassari, Sassari, Italy Purpose/Objective: Nasal vestibule (NV) tumors are rare entities, constituting less than 1% of all head and neck malignancies [1]. Managing these tumors presents significant challenges, primarily due to the anatomical complexity of the nasal region and the considerable impact on patient quality of life (QoL). Interventional radiotherapy (IRT-brachytherapy) has emerged as a recommended standard of care, offering local control rates comparable to surgery while preserving the integrity of nasal structures. However, there is a notable lack of comprehensive data on patient reported outcomes (PROs), underscoring the necessity for focused research to elucidate the QoL implications of IRT. Keywords: HyBIRT technique, Definitive tongue brachytherapy 2819